Financings in Brief: LifeCell
This article was originally published in The Gray Sheet
LifeCell: Woodlands, Texas-based firm files with the SEC for a secondary offering of 4.5 mil. shares of common stock -- including 4 mil. to be sold by the company and 500,000 to be sold by selling shareholders. LifeCell will use net proceeds for further development, sales and marketing of its AlloDerm dermal tissue graft product, as well as for working capital and general corporate purposes. Vector Securities International and Gruntal & Co., LLC are underwriters for the offering...
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.